3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Paclitaxel
8
Radiotherapy
7
Cisplatin
6
pembrolizumab
4
Fluorouracil
4
Surgical Procedures, Operative
3
Radiation
3
Oxaliplatin
3
Levoleucovorin
3
Leucovorin
3
Esophagectomy
3
Drug Therapy
3
Carboplatin
3
lenvatinib
2
durvalumab
2
Taxes
2
TP protocol
2
Radiotherapy, Intensity-Modulated
2
Nivolumab
2
Neoadjuvant Therapy
2
Irinotecan
2
Capecitabine
2
trifluridine tipiracil drug combination
1
tislelizumab
1
palbociclib
1
osimertinib
1
obinutuzumab
1
nedaplatin
1
naptumomab estafenatox
1
futibatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Esophageal Squamous Cell Carcinoma
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled